odemsertib   Click here for help

GtoPdb Ligand ID: 14624

Synonyms: compound 127 [PMID: 37402343] | VI-176 [1-2]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Odemsertib is the INN for a serine/threonine kinase inhibitor that targets IRAK1/4 for immunosuppression effect [1]. It is the active form of the oral prodrug odemsertib etifosfate (R906289; RG289; Rigel Therapeutics). The company code for odemsertib is R835.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 128.34
Molecular weight 499.54
XLogP 2.93
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC1CCC(CC1)N2C=C(C(=N2)C3=NC(=CC=C3F)F)NC(=O)C4=CSC(=N4)C5=CNN=C5
Isomeric SMILES CCOC1CCC(CC1)N2C=C(C(=N2)C3=C(C=CC(=N3)F)F)NC(=O)C4=CSC(=N4)C5=CNN=C5
InChI InChI=1S/C23H23F2N7O2S/c1-2-34-15-5-3-14(4-6-15)32-11-17(21(31-32)20-16(24)7-8-19(25)30-20)28-22(33)18-12-35-23(29-18)13-9-26-27-10-13/h7-12,14-15H,2-6H2,1H3,(H,26,27)(H,28,33)
InChI Key WCFCQFGVNHHQKA-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
The oral prodrug is utilised in clinical studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05308264 Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Phase 1/Phase 2 Interventional Rigel Pharmaceuticals